About Repros Therapeutics (NASDAQ:RPRX)
Repros Therapeutics, Inc. is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company's product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis. Enclomiphene is for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. The Company's Proellex product candidate for female reproductive health is a chemical entity, which acts as a selective blocker of the progesterone receptor. It is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis The Company has an active Investigational New Drug (IND) for the vaginal delivery of Proellex for the treatment of uterine fibroids.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research
- Sub-Industry: Pharmaceuticals
- Symbol: NASDAQ:RPRX
- CUSIP: 76028H20
- Web: www.reprosrx.com
Capitalization:- Market Cap: $16.36 million
- Outstanding Shares: 37,615,000
Average Prices:- 50 Day Moving Avg: $0.39
- 200 Day Moving Avg: $0.54
- 52 Week Range: $0.26 - $2.15
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -0.43
- P/E Growth: -0.020
Sales & Book Value:- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: ($0.01) per share
- Price / Book: -43.50
Profitability:- EBITDA: ($15,950,000.00)
- Net Margins: -56,062.07%
- Return on Equity: -412.64%
- Return on Assets: -212.24%
Debt:- Current Ratio: 1.81%
- Quick Ratio: 1.81%
Misc:- Average Volume: 1.03 million shs.
- Beta: 0.4
- Short Ratio: 0.92
Frequently Asked Questions for Repros Therapeutics (NASDAQ:RPRX)
What is Repros Therapeutics' stock symbol?
Repros Therapeutics trades on the NASDAQ under the ticker symbol "RPRX."
How were Repros Therapeutics' earnings last quarter?
Repros Therapeutics Inc. (NASDAQ:RPRX) issued its quarterly earnings results on Monday, August, 14th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.22) by $0.14. The business had revenue of $0.01 million for the quarter. Repros Therapeutics had a negative net margin of 56,062.07% and a negative return on equity of 412.64%. View Repros Therapeutics' Earnings History.
When will Repros Therapeutics make its next earnings announcement?
Where is Repros Therapeutics' stock going? Where will Repros Therapeutics' stock price be in 2017?
2 equities research analysts have issued 12 month price targets for Repros Therapeutics' stock. Their predictions range from $1.50 to $1.50. On average, they expect Repros Therapeutics' share price to reach $1.50 in the next year. View Analyst Ratings for Repros Therapeutics.
Are investors shorting Repros Therapeutics?
Repros Therapeutics saw a decline in short interest during the month of September. As of September 15th, there was short interest totalling 811,786 shares, a decline of 32.2% from the August 31st total of 1,197,977 shares. Based on an average daily trading volume, of 330,648 shares, the days-to-cover ratio is presently 2.5 days. Currently, 2.2% of the shares of the stock are short sold.
Who are some of Repros Therapeutics' key competitors?
Some companies that are related to Repros Therapeutics include Oncobiologics (ONS), Aptose Biosciences (APTO), Caladrius Biosciences (CLBS), OncoSec Medical Incorporated (ONCS), Burcon NutraScience Corp (BUR), Jaguar Animal Health (JAGX), OpGen (OPGN), Senestech (SNES), Oxford Pharmascience Group Plc (OXP), Transgenomic (PRPO), RXi Pharmaceuticals Corporation (RXII), Novogen Limited (NVGN), Metabolix (YTEN), Ampliphi Biosciences Corp (APHB), Synairgen plc (SNG), Ixico Plc (IXI), Roka Bioscience (ROKA) and Akers Biosciences (AKR).
Who are Repros Therapeutics' key executives?
Repros Therapeutics' management team includes the folowing people:
- Patrick P. Fourteau, Chairman of the Board
- Larry M. Dillaha M.D., President, Chief Executive Officer, Director
- Katherine A. Anderson CPA, Chief Financial Officer, Chief Accounting Officer, Secretary
- Joachim F. Wernicke, Chief Medical Officer
- Daniel F. Cain, Independent Director
- Nola E. Masterson, Independent Director
- Saira Ramasastry, Independent Director
- Michael G. Wyllie Ph.D., Independent Director
How do I buy Repros Therapeutics stock?
Shares of Repros Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Repros Therapeutics' stock price today?
One share of Repros Therapeutics stock can currently be purchased for approximately $0.44.
MarketBeat Community Rating for Repros Therapeutics (NASDAQ RPRX)MarketBeat's community ratings are surveys of what our community members think about Repros Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Repros Therapeutics (NASDAQ:RPRX) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating, 1 Buy Rating |
| Consensus Rating: | Buy (Score: 2.50) |
| Consensus Price Target: | $1.50 (244.83% upside) |
Consensus Price Target History for Repros Therapeutics (NASDAQ:RPRX)
Analysts' Ratings History for Repros Therapeutics (NASDAQ:RPRX)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/21/2017 | Laidlaw | Downgrade | Buy -> Neutral | | Medium |  |
| 1/30/2017 | S&P Equity Research | Boost Price Target | | $1.22 -> $1.50 | N/A | |
| 11/16/2016 | Ladenburg Thalmann Financial Services | Upgrade | Neutral -> Buy | | N/A | |
| 2/9/2016 | Piper Jaffray Companies | Reiterated Rating | Neutral | | N/A | |
| 12/4/2015 | Brean Capital | Reiterated Rating | Hold | | N/A | |
| 10/30/2015 | Bank of America Corporation | Downgrade | Neutral -> Underperform | | N/A | |
(Data available from 10/20/2015 forward)
Earnings History for Repros Therapeutics (NASDAQ:RPRX)Earnings History by Quarter for Repros Therapeutics (NASDAQ RPRX)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/6/2017 | | ($0.28) | | | | | N/A | |
| 8/14/2017 | Q2 2017 | ($0.22) | ($0.08) | | $0.01 million | View | N/A | |
| 5/9/2017 | Q1 2017 | ($0.15) | ($0.22) | | $0.01 million | View | N/A | |
| 3/31/2017 | Q4 2016 | ($0.17) | ($0.16) | | $0.01 million | View | N/A | |
| 11/8/2016 | Q3 2016 | ($0.18) | ($0.17) | | $0.01 million | View | N/A | |
| 8/9/2016 | Q216 | ($0.20) | ($0.18) | | $0.02 million | View | N/A | |
| 5/10/2016 | Q1 | ($0.22) | ($0.20) | | $0.02 million | View | N/A | |
| 3/14/2016 | Q4 | ($0.27) | ($0.26) | | $0.01 million | View | N/A | |
| 11/9/2015 | Q3 | ($0.29) | ($0.27) | | | View | N/A | |
| 8/10/2015 | Q2 | ($0.26) | ($0.32) | | | View | N/A | |
| 3/16/2015 | Q414 | ($0.34) | ($0.31) | | | View | N/A | |
| 11/10/2014 | Q314 | ($0.39) | ($0.32) | | | View | N/A | |
| 8/11/2014 | | ($0.37) | ($0.38) | | | View | N/A | |
| 5/12/2014 | Q114 | ($0.35) | ($0.37) | | | View | N/A | |
| 3/13/2014 | Q413 | ($0.29) | ($0.31) | | | View | N/A | |
| 8/7/2013 | Q213 | ($0.40) | ($0.38) | | | View | N/A | |
| 5/10/2013 | Q1 2013 | ($0.35) | ($0.41) | | | View | N/A | |
| 3/18/2013 | Q412 | ($0.28) | ($0.47) | $0.00 million | $0.00 million | View | N/A | |
| 11/13/2012 | Q312 | ($0.24) | ($0.30) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Repros Therapeutics (NASDAQ:RPRX)Current Year EPS Consensus Estimate: $-1.070 EPS
Next Year EPS Consensus Estimate: $-1.010 EPS
Dividend History for Repros Therapeutics (NASDAQ:RPRX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Repros Therapeutics (NASDAQ:RPRX)Insider Ownership Percentage: 2.50%
Institutional Ownership Percentage: 14.52%
Insider Trades by Quarter for Repros Therapeutics (NASDAQ:RPRX)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 12/9/2016 | Joseph Podolski | Insider | Buy | 20,000 | $1.60 | $32,000.00 | |
| 2/18/2016 | Joseph Podolski | CEO | Buy | 10,000 | $0.93 | $9,300.00 | |
| 1/7/2016 | Joseph Podolski | CEO | Buy | 11,677 | $1.18 | $13,778.86 | |
| 11/12/2014 | Joseph Podolski | CEO | Buy | 4,700 | $9.42 | $44,274.00 | |
| 11/12/2014 | Katherine Anderson | CFO | Buy | 3,500 | $9.41 | $32,935.00 | |
| 8/14/2014 | Joseph Podolski | CEO | Buy | 2,100 | $13.91 | $29,211.00 | |
| 8/14/2014 | Katherine Anderson | CFO | Buy | 2,000 | $13.85 | $27,700.00 | |
| 10/25/2013 | Joseph Podolski | CEO | Buy | 3,000 | $18.03 | $54,090.00 | |
| 10/25/2013 | Katherine Anderson | CFO | Buy | 1,000 | $17.90 | $17,900.00 | |
| 10/10/2013 | Katherine Anderson | CFO | Buy | 1,000 | $23.77 | $23,770.00 | |
| 2/1/2013 | Katherine Anderson | CFO | Buy | 1,000 | $11.89 | $11,890.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Repros Therapeutics (NASDAQ:RPRX)
Latest Headlines for Repros Therapeutics (NASDAQ:RPRX)
| Source: |
|
| Date | Headline |
|---|
 | 3 Biotech Stocks to Have on Your Watch-List in October
finance.yahoo.com - October 10 at 6:31 AM |
 | Repros Therapeutics Inc. (RPRX) Short Interest Update
www.americanbankingnews.com - September 30 at 3:02 AM |
 | Biotech Stocks on Investors' Radar -- Neothetics, Pieris Pharma, and Repros Therapeutics - PR Newswire (press release)
www.prnewswire.com - September 27 at 11:23 PM |
| Contrasting Repros Therapeutics (RPRX) & Its Rivals
www.americanbankingnews.com - September 15 at 8:46 PM |
| CASI Pharmaceuticals (CASI) & Repros Therapeutics (RPRX) Critical Review
www.americanbankingnews.com - August 30 at 10:24 PM |
 | Mid-Afternoon Market Update: Crude Oil Down 2%; Neff Shares Spike Higher - Benzinga
www.benzinga.com - August 14 at 3:24 PM |
 | Repros Therapeutics Inc.® Reports Second Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - August 14 at 3:24 PM |
| Repros Therapeutics Inc.® Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 14 at 3:24 PM |
| Repros Therapeutics reports 2Q loss
finance.yahoo.com - August 14 at 3:24 PM |
| Repros Therapeutics Inc. (NASDAQ:RPRX) Issues Quarterly Earnings Results
www.americanbankingnews.com - August 14 at 10:47 AM |
| Short Interest in Repros Therapeutics Inc. (NASDAQ:RPRX) Drops By 47.7%
www.americanbankingnews.com - August 13 at 2:20 AM |
| Repros Therapeutics Inc. (RPRX) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - August 7 at 10:48 AM |
 | Repros (RPRX) Q2 Earnings: What's in Store for the Stock? - Nasdaq
www.nasdaq.com - August 2 at 7:17 AM |
| Repros (RPRX) Q2 Earnings: What's in Store for the Stock?
finance.yahoo.com - August 2 at 7:17 AM |
| Repros Therapeutics Inc. (RPRX) Lowered to "Neutral" at Laidlaw
www.americanbankingnews.com - July 21 at 9:30 AM |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Repros Therapeutics, Inc ... - PR Newswire (press release)
www.prnewswire.com - July 19 at 7:23 AM |
| Repros' Proellex Stays on Partial Clinical Hold, Shares Fall
finance.yahoo.com - July 19 at 7:22 AM |
| INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Repros Therapeutics Inc.
finance.yahoo.com - July 17 at 8:33 PM |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Repros Therapeutics, Inc. - RPRX
finance.yahoo.com - July 17 at 3:31 PM |
| SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Repros Therapeutics Inc. (RPRX)
finance.yahoo.com - July 17 at 3:31 PM |
 | Repros Therapeutics (RPRX) Reports Proellex Development Program to Remain on Partial Clinical Hold by the FDA - StreetInsider.com
www.streetinsider.com - July 17 at 8:11 AM |
| Repros Announces Proellex® Development Program Will Remain on Partial Clinical Hold by the FDA
finance.yahoo.com - July 17 at 8:11 AM |
| Repros Therapeutics Inc. (RPRX) Short Interest Up 165.8% in June
www.americanbankingnews.com - July 16 at 7:14 AM |
| Repros Announces Pricing of $3.0 Million Public Offering Of Common Stock And Warrants To Purchase Common Stock - GlobeNewswire (press release)
globenewswire.com - May 18 at 10:57 AM |
| Repros Therapeutics (RPRX) Plans Offering of Common Stock, Warrants - StreetInsider.com
www.streetinsider.com - May 18 at 10:57 AM |
| Repros Therapeutics (RPRX) Plans Offering of Common Stock, Warrants
www.streetinsider.com - May 17 at 7:32 PM |
| Repros Therapeutics Inc.® Reports First Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - May 10 at 7:50 PM |
 | Repros Therapeutics reports 1Q loss
marketbeat.com - May 9 at 5:44 PM |
| What's in the Cards for Repros (RPRX) this Earnings Season? - Nasdaq
www.nasdaq.com - May 6 at 12:55 AM |
 | What's in the Cards for Repros (RPRX) this Earnings Season?
www.zacks.com - May 5 at 7:54 PM |
| Repros' Proellex Continues to be Under Partial Clinical Hold
www.zacks.com - April 11 at 9:58 AM |
| Repros Therapeutics (RPRX) Names Larry Dillaha as CEO
www.streetinsider.com - April 10 at 7:06 PM |
 | FDA continues partial clinical hold for Repros Therapeutics' fibroids drug
seekingalpha.com - April 10 at 10:22 AM |
 | Repros Therapeutics Inc.® Reports Fourth Quarter and Year End 2016 Financial Results
us.rd.yahoo.com - March 31 at 7:46 PM |
| REPROS THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition
us.rd.yahoo.com - March 31 at 7:46 PM |
| Repros (RPRX) Q4 Earnings: What's in Store for the Stock? - Nasdaq
www.nasdaq.com - March 8 at 7:52 PM |
| REPROS THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhi
biz.yahoo.com - February 8 at 11:34 PM |
| Repros Therapeutics (RPRX) Names Larry Dillaha as Interim CEO - StreetInsider.com
www.streetinsider.com - February 4 at 7:41 PM |
 | CEO leaves Woodlands-based drug company; interim named
www.bizjournals.com - February 3 at 11:38 PM |
| Repros Therapeutics (RPRX) Names Larry Dillaha as Interim CEO
www.streetinsider.com - February 3 at 3:10 AM |
| 9:16 am Repros Therapeutics President and CEO Joseph S. Podolski is leaving his position to pursue other interests; Larry Dillaha, M.D., CEO of CavtheRx, was appointed interim President and CEO, effective immediately
us.rd.yahoo.com - February 3 at 3:10 AM |
| Repros Therapeutics (RPRX) Granted FDA End of Phase 2 Meeting on Proellex
www.streetinsider.com - February 1 at 3:11 AM |
| Repros Therapeutics (RPRX) Granted FDA End of Phase 2 Meeting on Proellex - StreetInsider.com
www.streetinsider.com - January 30 at 8:25 PM |
Repros Therapeutics (RPRX) Chart for Friday, October, 20, 2017
